SlowBull
The Business Brief MONDAY, 10 AUGUST 2026
← All stories
Markets

Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

1 source ·1 article ·3h ago

Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·3h ago

Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.